Comparison of three research models of portal hypertension in mice: macroscopic, histological and portal pressure evaluation.
The characterization of mice models of portal hypertension (PHT) is lacking in the literature. Therefore, the aim of the present study was to make a histological approach during development of PHT in two models of cirrhosis with PHT compared with one model of isolated PHT. The model of isolated PHT was developed by partial portal vein ligation (PPVL). Two portal hypertensive cirrhotic mice models were developed either by common bile duct ligation (CBDL) or administration of carbon tetrachloride (CCl(4)) subcutaneously (twice weekly, 1 ml/kg). These models represent, respectively, a secondary biliary cirrhosis and alcoholic cirrhosis. Mice were killed at several time points to evaluate liver changes by histological and ultrastructural methods. A correlation was made with portal pressure measurements. Histology revealed the absence of fibrosis or cirrhosis in PPVL mice. They developed an isolated portal hypertension. After CBDL induction, the mice developed the characteristics of cirrhosis after 6 weeks, with simultaneous increase in portal pressures. Fifty percent of the mice had ascites at that time point. Sixteen weeks after administration of CCl(4), a micronodular cirrhotic aspect of the liver was seen associated with signs of portal hypertension. This is the first descriptive study of three widely used animal models in mice, allowing the study of pathophysiological changes in cirrhosis and portal hypertension. The PPVL in mice leads to a model of isolated portal hypertension. Secondary biliary cirrhosis developed after 6 weeks of common bile duct ligation in 50% of the mice that developed ascites. Subcutaneous injection of CCl(4) for 16 weeks induces cirrhosis and portal hypertension, without ascites. Moreover, the present study is the first description of a cirrhotic model in mice developed by subcutaneous injections of CCl(4). Well-described mice models will facilitate use of knock-out or transgenic mice and lead to a better understanding of the underlying molecular pathways in the field of portal hypertension and cirrhosis.
Geerts
Anja M
AM
Department of Hepatology & Gastroenterology, Ghent Univerity Hospital, Ghent, Belgium. anja.geerts@ugent.be
Vanheule
Eline
E
Praet
Marleen
M
Van Vlierberghe
Hans
H
De Vos
Martine
M
Colle
Isabelle
I
D000818:Animals; D001201:Ascites / Q000473:pathology / Q000503:physiopathology; D002251:Carbon Tetrachloride; D003135:Common Bile Duct; D018450:Disease Progression; D006975:Hypertension, Portal / Q000473:pathology* / Q000503:physiopathology; D007279:Injections, Subcutaneous; D008026:Ligation; D008099:Liver / Q000473:pathology / Q000648:ultrastructure; D008105:Liver Cirrhosis, Biliary; D008106:Liver Cirrhosis, Experimental / Q000473:pathology / Q000503:physiopathology; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D008854:Microscopy, Electron; D023421:Models, Animal; D017082:Portal Pressure; D011169:Portal Vein; D013194:Staining and Labeling
D002251:Carbon Tetrachloride